Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000 cr nutraceuticals market
Mamaearth-parent Honasa Consumer acquires 58% stake in Fluence Pharma at ₹135 crore enterprise value, with the remaining 42% to be picked up in two tranches over 5-7 years. The deal launches new subsidiary Honasa Health and marks entry into India's ₹16,000 crore nutraceuticals segment growing at 11%, leveraging Fluence's 3,000-dermatologist network.
Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma at ₹135 crore EV, with remaining 42% over 5-7 years. Marks Mamaearth-parent's entry into India's ₹16,000 crore nutraceuticals market via new subsidiary Honasa Health.